Mechanistically, using real-time quantitative polymerase chain reaction (qPCR) experiments prior to disease induction therapy, Wang et al. [117] detected increased gene expression levels of m6A-modified methylases (e.g., METTL3, METTL14, WTAP) and demethylases (e.g., FTO and ALKBH5) in ETV6/RUNX1-positive ALL patients, but decreased significantly after induction therapy. The gene discussed is RUNX1; the disease is acute lymphoblastic leukemia.